Ondine Biomedical Inc.

LSE:OBI.L

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

💻 Telehealth

Location

Canada

Market Cap

USD 87.59 M

Share Price

USD 0.20

Avg Daily Volume

136,629

Change (1 day)

-0.06%

Change (1 year)

87.44%

Change (YTD)

78.55%

Ondine Biomedical Inc. Revenue for the year ending December 31, 2024

Ondine Biomedical Inc. Revenue is NA for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Ondine Biomedical Inc. Revenue for the year ending December 31, 2023 was USD 907.66 K, a 92.85% change year over year.
Ondine Biomedical Inc. Revenue for the year ending December 31, 2022 was USD 470.65 K, a -76.83% change year over year.
Ondine Biomedical Inc. Revenue for the year ending December 31, 2021 was USD 2.03 M, a 44.50% change year over year.
Ondine Biomedical Inc. Revenue for the year ending December 31, 2020 was USD 1.41 M, a 293.72% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

LSE: OBI.L

Ondine Biomedical Inc.

CEO	Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA
IPO Date	Dec. 6, 2021
Location	Canada
Headquarters	1100 Melville Street
Employees	18
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals 💻 Telehealth

Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.